 Folate Receptor 1
"Folate Receptor 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of GPI-anchored folate receptors that is expressed in tissues of epithelial origin. This protein is also identified as an ovarian-tumor-specific antigen.
| Descriptor ID |
D058975
|
| MeSH Number(s) |
D12.776.157.530.450.074.500.299.500.500 D12.776.395.550.448.370.500 D12.776.543.484.500.370.500 D12.776.543.550.418.370.500 D12.776.543.585.450.074.500.224.500.500 D12.776.543.750.052.500 D23.050.285.384
|
| Concept/Terms |
Folate Receptor 1- Folate Receptor 1
- Receptor 1, Folate
- Ovarian Tumor-Associated Antigen MOv18
- Ovarian Tumor Associated Antigen MOv18
- Folate Receptor alpha
- Receptor alpha, Folate
|
Below are MeSH descriptors whose meaning is more general than "Folate Receptor 1".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Carrier Proteins [D12.776.157]
- Membrane Transport Proteins [D12.776.157.530]
- Ion Pumps [D12.776.157.530.450]
- Anion Transport Proteins [D12.776.157.530.450.074]
- Organic Anion Transporters [D12.776.157.530.450.074.500]
- Folic Acid Transporters [D12.776.157.530.450.074.500.299]
- Folate Receptors, GPI-Anchored [D12.776.157.530.450.074.500.299.500]
- Folate Receptor 1 [D12.776.157.530.450.074.500.299.500.500]
- Glycoproteins [D12.776.395]
- Membrane Glycoproteins [D12.776.395.550]
- GPI-Linked Proteins [D12.776.395.550.448]
- Folate Receptors, GPI-Anchored [D12.776.395.550.448.370]
- Folate Receptor 1 [D12.776.395.550.448.370.500]
- Membrane Proteins [D12.776.543]
- Lipid-Linked Proteins [D12.776.543.484]
- GPI-Linked Proteins [D12.776.543.484.500]
- Folate Receptors, GPI-Anchored [D12.776.543.484.500.370]
- Folate Receptor 1 [D12.776.543.484.500.370.500]
- Membrane Glycoproteins [D12.776.543.550]
- GPI-Linked Proteins [D12.776.543.550.418]
- Folate Receptors, GPI-Anchored [D12.776.543.550.418.370]
- Folate Receptor 1 [D12.776.543.550.418.370.500]
- Membrane Transport Proteins [D12.776.543.585]
- Ion Pumps [D12.776.543.585.450]
- Anion Transport Proteins [D12.776.543.585.450.074]
- Organic Anion Transporters [D12.776.543.585.450.074.500]
- Folic Acid Transporters [D12.776.543.585.450.074.500.224]
- Folate Receptors, GPI-Anchored [D12.776.543.585.450.074.500.224.500]
- Folate Receptor 1 [D12.776.543.585.450.074.500.224.500.500]
- Receptors, Cell Surface [D12.776.543.750]
- Folate Receptors, GPI-Anchored [D12.776.543.750.052]
- Folate Receptor 1 [D12.776.543.750.052.500]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Neoplasm [D23.050.285]
- Folate Receptor 1 [D23.050.285.384]
Below are MeSH descriptors whose meaning is more specific than "Folate Receptor 1".
This graph shows the total number of publications written about "Folate Receptor 1" by people in UAMS Profiles by year, and whether "Folate Receptor 1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 0 | 1 | | 2020 | 1 | 2 | 3 | | 2019 | 2 | 0 | 2 | | 2018 | 1 | 1 | 2 | | 2017 | 2 | 1 | 3 | | 2016 | 0 | 2 | 2 | | 2015 | 1 | 1 | 2 | | 2012 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Folate Receptor 1" by people in Profiles over the past ten years.
-
Samanta D, Ramakrishnaiah R, Frye RE. Complex Heterozygous Polymerase Gamma Mutation and Cerebral Folate Deficiency in a Child with Refractory Partial Status. Neurol India. 2022 Sep-Oct; 70(5):2265-2267.
-
Block MS, Dietz AB, Gustafson MP, Kalli KR, Erskine CL, Youssef B, Vijay GV, Allred JB, Pavelko KD, Strausbauch MA, Lin Y, Grudem ME, Jatoi A, Klampe CM, Wahner-Hendrickson AE, Weroha SJ, Glaser GE, Kumar A, Langstraat CL, Solseth ML, Deeds MC, Knutson KL, Cannon MJ. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nat Commun. 2020 10 14; 11(1):5173.
-
Frye RE, Rossignol DA, Scahill L, McDougle CJ, Huberman H, Quadros EV. Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder. Semin Pediatr Neurol. 2020 10; 35:100835.
-
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020 05; 157(2):379-385.
-
Birrer MJ, Betella I, Martin LP, Moore KN. Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age? Oncologist. 2019 04; 24(4):425-429.
-
Samanta D, Ramakrishnaiah R, Frye RE. Complex heterozygous polymerase gamma mutation and cerebral folate deficiency in a child with refractory partial status. Neurol India. 2019 Jan-Feb; 67(1):259-260.
-
Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. Clin Cancer Res. 2019 03 15; 25(6):1727-1736.
-
Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
-
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018 Jan; 14(2):123-136.
-
Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ. Characterization of folate receptor alpha (FRa) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRa-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017 11; 147(2):402-407.
-
Frye RE, Wynne R, Rose S, Slattery J, Delhey L, Tippett M, Kahler SG, Bennuri SC, Melnyk S, Sequeira JM, Quadros EV. Thyroid dysfunction in children with autism spectrum disorder is associated with folate receptor a autoimmune disorder. J Neuroendocrinol. 2017 03; 29(3).
-
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 01; 35(10):1112-1118.
-
Frye RE, Slattery J, Delhey L, Furgerson B, Strickland T, Tippett M, Sailey A, Wynne R, Rose S, Melnyk S, Jill James S, Sequeira JM, Quadros EV. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry. 2018 02; 23(2):247-256.
-
Driver BR, Barrios R, Ge Y, Haque A, Tacha D, Cagle PT. Folate Receptor a Expression Level Correlates With Histologic Grade in Lung Adenocarcinoma. Arch Pathol Lab Med. 2016 Jul; 140(7):682-5.
-
Rychahou P, Haque F, Shu Y, Zaytseva Y, Weiss HL, Lee EY, Mustain W, Valentino J, Guo P, Evers BM. Delivery of RNA nanoparticles into colorectal cancer metastases following systemic administration. ACS Nano. 2015 Feb 24; 9(2):1108-16.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|